NeoStem, Inc. and AllCells, LLC to collaborate with Mount Sinai as part of $8.8 million Grant to Further Stem Cell Research
April 16, 2015 – Icahn School of Medicine at Mount Sinai (ISSMM) will be able to further develop new blood treatments for chemotherapy-resistant blood cancer and other genetic blood disorders thanks to an $8.8 million grant from the New York State Stem …
Mount Sinai Genetic Testing Laboratory Launches More Accurate Carrier Screening Test for Spinal Muscular Atrophy
February 11, 2014 – The Icahn School of Medicine at Mount Sinai today announced the launch of a more accurate carrier screening test for spinal muscular atrophy (SMA), one of the most common and severe autosomal recessive disorders. This new test will help prospective …
Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
May 24, 2013 – The Icahn School of Medicine at Mount Sinai has granted Cellular Dynamics International (CDI) exclusive license rights to commercially develop cardiomyocyte progenitors for in vivo cell therapy and regenerative medicine applications. These cells are capable of further differentiation into the multiple cell …
Mount Sinai Invents Gene Signature to Identify Individuals with Cirrhosis at High-Risk for Liver Cancer
April 17, 2013 – Researchers at the Icahn School of Medicine at Mount Sinai have developed the first-ever gene test that could be used to identify patients with cirrhosis who are at highest risk of developing the most common type of liver cancer, …
The Icahn School of Medicine at Mount Sinai Partners with Genisphere to Develop Rapid, High-Throughput Allergy Test
January 31, 2013 – The Icahn School of Medicine at Mount Sinai and Genisphere have agreed to jointly develop a new allergy test that will quickly and effectively characterize patients’ food allergies. The peptide-bead-based test will be high-throughput, semi-automatic and accurate, surpassing …
Mount Sinai School of Medicine and MRC Technology To Collaborate On Monoclonal Antibody Production and Humanization
April 3, 2012 – The Mount Sinai Medical Center and MRC Technology (MRCT), the technology transfer organization for the United Kingdom’s prestigious Medical Research Council, have reached an agreement to collaborate on the development of monoclonal antibodies that can be commercialized as …